Lotrisone is a topical medication that combines two active ingredients: clotrimazole (an antifungal agent) and betamethasone dipropionate (a potent corticosteroid). It is supplied in a 10 g tube and is used to treat skin conditions where a fungal infection is accompanied by inflammation or itching. In Hong Kong, Lotrisone is classified as a prescription-only medicine and is regulated by the Department of Health’s Pharmacy and Poisons Board.
Clotrimazole belongs to the azole class of antifungals. It inhibits the enzyme lanosterol 14α-demethylase, a key step in fungal cell-membrane synthesis. By disrupting the production of ergosterol, clotrimazole weakens the fungal cell membrane, leading to leakage of cellular contents and ultimately killing or inhibiting the growth of susceptible fungi (e.g., Candida and dermatophytes).
Betamethasone dipropionate is a synthetic glucocorticoid with high anti-inflammatory potency. It binds to intracellular glucocorticoid receptors, altering gene transcription to reduce the production of inflammatory mediators such as prostaglandins and cytokines. This results in decreased redness, swelling, and itching.
When applied together, the antifungal component treats the infection while the corticosteroid rapidly relieves the associated inflammation, allowing faster symptom resolution than an antifungal alone.
Lotrisone is approved for the topical treatment of fungal skin infections that also exhibit inflammation, including:
The medication is intended for adults; use in children should be directed by a healthcare professional, taking into account the higher risk of steroid-related skin thinning.
Current peer-reviewed literature does not support widespread off-label use of Lotrisone beyond the indications listed above. Any consideration of alternative applications-such as treatment of seborrheic dermatitis or non-fungal eczema-must be guided by a qualified clinician and based on individual risk-benefit assessment.
These reactions are typically mild and transient. If they persist beyond a few days, patients should contact their healthcare provider.
This article provides educational information about Lotrisone and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Lotrisone contains a potent corticosteroid, which can cause thinning of facial skin with prolonged use. It may be used on the face for a short duration (typically ≤ 7 days) if the benefits outweigh the risks and under medical supervision.
A new rash could indicate an allergic reaction or irritation. Discontinue use immediately and seek medical evaluation to determine whether an alternative therapy is needed.
Topical corticosteroids are classified as Category C in Hong Kong, meaning risk cannot be ruled out. Use only if the prescribing clinician determines that the potential benefits justify the possible risks to the fetus.
After opening, keep the tube sealed and store at room temperature. Most manufacturers recommend using the product within 3 months of opening, provided the appearance and smell remain unchanged.
Occlusive dressings can increase steroid absorption and heighten the risk of systemic effects. Avoid covering the treated area with a bandage unless specifically instructed by a healthcare professional.
Topical clotrimazole has minimal systemic absorption, so significant interactions with oral antifungals (e.g., fluconazole) are unlikely. Nonetheless, inform your prescriber of all medications you are taking.
Lotrisone combines clotrimazole with betamethasone dipropionate, providing both antifungal action and potent anti-inflammatory relief. Plain clotrimazole treats the infection but does not address associated inflammation as quickly.
Topical corticosteroids can be detected in drug testing if applied over large areas. Athletes should verify with their sport’s governing body and may need to disclose use if required.
Use in children is possible but requires careful dosing and a limited treatment duration due to the risk of skin atrophy. A pediatrician should evaluate the need and supervise therapy.
Apply the missed dose as soon as you remember, then continue with the regular dosing schedule. Do not double the dose to compensate for the missed application.